Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.86
+0.36000.89%
Post-market: 41.000.1400+0.34%18:01 EDT
Volume:706.60K
Turnover:28.58M
Market Cap:2.92B
PE:-8.76
High:41.45
Open:39.27
Low:39.00
Close:40.50
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:0.67
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.82
PE(LYR):-8.76

Loading ...

Vera Therapeutics (VERA): Valuation Insights Following Positive Phase 3 Data, FDA Filing, and Yale Investment

Simply Wall St.
·
Nov 16, 2025

Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data

Simply Wall St.
·
Nov 15, 2025

Vera Therapeutics SVP Finance Joseph R. Young Reports Sale of Common Shares

Reuters
·
Nov 14, 2025

Stock Track | Vera Therapeutics Soars 7.48% on FDA Application for Kidney Disease Treatment Atacicept

Stock Track
·
Nov 10, 2025

Stock Track | Vera Therapeutics Soars 5.83% Pre-market on FDA Application for Kidney Disease Treatment

Stock Track
·
Nov 10, 2025

Vera Therapeutics to Present at TD Cowen Immunology & Inflammation Summit

Reuters
·
Nov 10, 2025

Vera Therapeutics Submits Kidney Disease Therapy Biologics License Application to FDA; Shares Up Pre-Bell

MT Newswires Live
·
Nov 10, 2025

Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 10, 2025

Stock Track | Vera Therapeutics Soars 6.24% After-Hours on FDA Application for Breakthrough IgA Nephropathy Treatment

Stock Track
·
Nov 08, 2025

Vera Therapeutics submits BLA for atacicept to FDA

TIPRANKS
·
Nov 08, 2025

Vera Therapeutics Submits FDA Application for Atacicept in IgA Nephropathy

Reuters
·
Nov 08, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA Through Accelerated Approval Program for Atacicept for the Treatment of Adults With Iga Nephropathy

THOMSON REUTERS
·
Nov 08, 2025

Vera Therapeutics Inc - Origin Phase 3 Trial Meets Primary Endpoint With 46% Reduction

THOMSON REUTERS
·
Nov 08, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 08, 2025

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 08, 2025

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Nov 07, 2025

Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating

TIPRANKS
·
Nov 07, 2025

Vera Therapeutics Announces Promising Phase 3 Trial Results

TIPRANKS
·
Nov 06, 2025

Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept

TIPRANKS
·
Nov 06, 2025

Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy

Reuters
·
Nov 06, 2025